0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Generic and Biosimilar Pharmaceuticals Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-26H10536
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global and United States Generic and Biosimilar Pharmaceuticals Market Report Forecast 2022 2028
BUY CHAPTERS

Global Generic and Biosimilar Pharmaceuticals Market Research Report 2025

Code: QYRE-Auto-26H10536
Report
July 2025
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Generic and Biosimilar Pharmaceuticals Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Generic and Biosimilar Pharmaceuticals Market

Generic and Biosimilar Pharmaceuticals Market

The global market for Generic and Biosimilar Pharmaceuticals was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Generic and Biosimilar Pharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic and Biosimilar Pharmaceuticals.
The Generic and Biosimilar Pharmaceuticals market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Generic and Biosimilar Pharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic and Biosimilar Pharmaceuticals companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Generic and Biosimilar Pharmaceuticals Market Report

Report Metric Details
Report Name Generic and Biosimilar Pharmaceuticals Market
CAGR 5%
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, 3sbio, Changchun High Tech, CP Guojian, Biotech, Gelgen, Innovent, Dong Bao, Ganlee
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Generic and Biosimilar Pharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Generic and Biosimilar Pharmaceuticals Market report?

Ans: The main players in the Generic and Biosimilar Pharmaceuticals Market are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, 3sbio, Changchun High Tech, CP Guojian, Biotech, Gelgen, Innovent, Dong Bao, Ganlee

What are the Application segmentation covered in the Generic and Biosimilar Pharmaceuticals Market report?

Ans: The Applications covered in the Generic and Biosimilar Pharmaceuticals Market report are Tumor, Diabetes, Cardiovascular, Hemophilia, Other

What are the Type segmentation covered in the Generic and Biosimilar Pharmaceuticals Market report?

Ans: The Types covered in the Generic and Biosimilar Pharmaceuticals Market report are Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccines, Other

Recommended Reports

Generic & Biosimilars

Pharmaceutical Processing

Diagnostics & Devices

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Generic and Biosimilar Pharmaceuticals Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Other
1.3 Market by Application
1.3.1 Global Generic and Biosimilar Pharmaceuticals Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Generic and Biosimilar Pharmaceuticals Market Perspective (2020-2031)
2.2 Global Generic and Biosimilar Pharmaceuticals Growth Trends by Region
2.2.1 Global Generic and Biosimilar Pharmaceuticals Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Generic and Biosimilar Pharmaceuticals Historic Market Size by Region (2020-2025)
2.2.3 Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Region (2026-2031)
2.3 Generic and Biosimilar Pharmaceuticals Market Dynamics
2.3.1 Generic and Biosimilar Pharmaceuticals Industry Trends
2.3.2 Generic and Biosimilar Pharmaceuticals Market Drivers
2.3.3 Generic and Biosimilar Pharmaceuticals Market Challenges
2.3.4 Generic and Biosimilar Pharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Generic and Biosimilar Pharmaceuticals Players by Revenue
3.1.1 Global Top Generic and Biosimilar Pharmaceuticals Players by Revenue (2020-2025)
3.1.2 Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Players (2020-2025)
3.2 Global Generic and Biosimilar Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Generic and Biosimilar Pharmaceuticals Revenue
3.4 Global Generic and Biosimilar Pharmaceuticals Market Concentration Ratio
3.4.1 Global Generic and Biosimilar Pharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic and Biosimilar Pharmaceuticals Revenue in 2024
3.5 Global Key Players of Generic and Biosimilar Pharmaceuticals Head office and Area Served
3.6 Global Key Players of Generic and Biosimilar Pharmaceuticals, Product and Application
3.7 Global Key Players of Generic and Biosimilar Pharmaceuticals, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic and Biosimilar Pharmaceuticals Breakdown Data by Type
4.1 Global Generic and Biosimilar Pharmaceuticals Historic Market Size by Type (2020-2025)
4.2 Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Type (2026-2031)
5 Generic and Biosimilar Pharmaceuticals Breakdown Data by Application
5.1 Global Generic and Biosimilar Pharmaceuticals Historic Market Size by Application (2020-2025)
5.2 Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Generic and Biosimilar Pharmaceuticals Market Size (2020-2031)
6.2 North America Generic and Biosimilar Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Generic and Biosimilar Pharmaceuticals Market Size by Country (2020-2025)
6.4 North America Generic and Biosimilar Pharmaceuticals Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Generic and Biosimilar Pharmaceuticals Market Size (2020-2031)
7.2 Europe Generic and Biosimilar Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Generic and Biosimilar Pharmaceuticals Market Size by Country (2020-2025)
7.4 Europe Generic and Biosimilar Pharmaceuticals Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size (2020-2031)
8.2 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Region (2020-2025)
8.4 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Generic and Biosimilar Pharmaceuticals Market Size (2020-2031)
9.2 Latin America Generic and Biosimilar Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Generic and Biosimilar Pharmaceuticals Market Size by Country (2020-2025)
9.4 Latin America Generic and Biosimilar Pharmaceuticals Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size (2020-2031)
10.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country (2020-2025)
10.4 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Generic and Biosimilar Pharmaceuticals Introduction
11.1.4 Roche Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Generic and Biosimilar Pharmaceuticals Introduction
11.2.4 Amgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Introduction
11.3.4 AbbVie Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.3.5 AbbVie Recent Development
11.4 Sanofi-Aventis
11.4.1 Sanofi-Aventis Company Details
11.4.2 Sanofi-Aventis Business Overview
11.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Introduction
11.4.4 Sanofi-Aventis Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.4.5 Sanofi-Aventis Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Introduction
11.5.4 Johnson & Johnson Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Introduction
11.6.4 Pfizer Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Introduction
11.7.4 Novo Nordisk Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Introduction
11.8.4 Eli Lilly Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Generic and Biosimilar Pharmaceuticals Introduction
11.9.4 Novartis Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Generic and Biosimilar Pharmaceuticals Introduction
11.10.4 Merck Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.10.5 Merck Recent Development
11.11 3sbio
11.11.1 3sbio Company Details
11.11.2 3sbio Business Overview
11.11.3 3sbio Generic and Biosimilar Pharmaceuticals Introduction
11.11.4 3sbio Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.11.5 3sbio Recent Development
11.12 Changchun High Tech
11.12.1 Changchun High Tech Company Details
11.12.2 Changchun High Tech Business Overview
11.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Introduction
11.12.4 Changchun High Tech Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.12.5 Changchun High Tech Recent Development
11.13 CP Guojian
11.13.1 CP Guojian Company Details
11.13.2 CP Guojian Business Overview
11.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Introduction
11.13.4 CP Guojian Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.13.5 CP Guojian Recent Development
11.14 Biotech
11.14.1 Biotech Company Details
11.14.2 Biotech Business Overview
11.14.3 Biotech Generic and Biosimilar Pharmaceuticals Introduction
11.14.4 Biotech Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.14.5 Biotech Recent Development
11.15 Gelgen
11.15.1 Gelgen Company Details
11.15.2 Gelgen Business Overview
11.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Introduction
11.15.4 Gelgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.15.5 Gelgen Recent Development
11.16 Innovent
11.16.1 Innovent Company Details
11.16.2 Innovent Business Overview
11.16.3 Innovent Generic and Biosimilar Pharmaceuticals Introduction
11.16.4 Innovent Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.16.5 Innovent Recent Development
11.17 Dong Bao
11.17.1 Dong Bao Company Details
11.17.2 Dong Bao Business Overview
11.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Introduction
11.17.4 Dong Bao Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.17.5 Dong Bao Recent Development
11.18 Ganlee
11.18.1 Ganlee Company Details
11.18.2 Ganlee Business Overview
11.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Introduction
11.18.4 Ganlee Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
11.18.5 Ganlee Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Generic and Biosimilar Pharmaceuticals Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Monoclonal Antibodies
 Table 3. Key Players of Interferon
 Table 4. Key Players of Erythropoietin
 Table 5. Key Players of Insulin
 Table 6. Key Players of Vaccines
 Table 7. Key Players of Other
 Table 8. Global Generic and Biosimilar Pharmaceuticals Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Generic and Biosimilar Pharmaceuticals Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Generic and Biosimilar Pharmaceuticals Market Size by Region (2020-2025) & (US$ Million)
 Table 11. Global Generic and Biosimilar Pharmaceuticals Market Share by Region (2020-2025)
 Table 12. Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 13. Global Generic and Biosimilar Pharmaceuticals Market Share by Region (2026-2031)
 Table 14. Generic and Biosimilar Pharmaceuticals Market Trends
 Table 15. Generic and Biosimilar Pharmaceuticals Market Drivers
 Table 16. Generic and Biosimilar Pharmaceuticals Market Challenges
 Table 17. Generic and Biosimilar Pharmaceuticals Market Restraints
 Table 18. Global Generic and Biosimilar Pharmaceuticals Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global Generic and Biosimilar Pharmaceuticals Market Share by Players (2020-2025)
 Table 20. Global Top Generic and Biosimilar Pharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic and Biosimilar Pharmaceuticals as of 2024)
 Table 21. Ranking of Global Top Generic and Biosimilar Pharmaceuticals Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by Generic and Biosimilar Pharmaceuticals Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of Generic and Biosimilar Pharmaceuticals, Headquarters and Area Served
 Table 24. Global Key Players of Generic and Biosimilar Pharmaceuticals, Product and Application
 Table 25. Global Key Players of Generic and Biosimilar Pharmaceuticals, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Generic and Biosimilar Pharmaceuticals Market Size by Type (2020-2025) & (US$ Million)
 Table 28. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2020-2025)
 Table 29. Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 30. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2026-2031)
 Table 31. Global Generic and Biosimilar Pharmaceuticals Market Size by Application (2020-2025) & (US$ Million)
 Table 32. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2020-2025)
 Table 33. Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 34. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2026-2031)
 Table 35. North America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. North America Generic and Biosimilar Pharmaceuticals Market Size by Country (2020-2025) & (US$ Million)
 Table 37. North America Generic and Biosimilar Pharmaceuticals Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Europe Generic and Biosimilar Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe Generic and Biosimilar Pharmaceuticals Market Size by Country (2020-2025) & (US$ Million)
 Table 40. Europe Generic and Biosimilar Pharmaceuticals Market Size by Country (2026-2031) & (US$ Million)
 Table 41. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Region (2020-2025) & (US$ Million)
 Table 43. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Region (2026-2031) & (US$ Million)
 Table 44. Latin America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Latin America Generic and Biosimilar Pharmaceuticals Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Generic and Biosimilar Pharmaceuticals Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 48. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country (2020-2025) & (US$ Million)
 Table 49. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country (2026-2031) & (US$ Million)
 Table 50. Roche Company Details
 Table 51. Roche Business Overview
 Table 52. Roche Generic and Biosimilar Pharmaceuticals Product
 Table 53. Roche Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 54. Roche Recent Development
 Table 55. Amgen Company Details
 Table 56. Amgen Business Overview
 Table 57. Amgen Generic and Biosimilar Pharmaceuticals Product
 Table 58. Amgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 59. Amgen Recent Development
 Table 60. AbbVie Company Details
 Table 61. AbbVie Business Overview
 Table 62. AbbVie Generic and Biosimilar Pharmaceuticals Product
 Table 63. AbbVie Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 64. AbbVie Recent Development
 Table 65. Sanofi-Aventis Company Details
 Table 66. Sanofi-Aventis Business Overview
 Table 67. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product
 Table 68. Sanofi-Aventis Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 69. Sanofi-Aventis Recent Development
 Table 70. Johnson & Johnson Company Details
 Table 71. Johnson & Johnson Business Overview
 Table 72. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product
 Table 73. Johnson & Johnson Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 74. Johnson & Johnson Recent Development
 Table 75. Pfizer Company Details
 Table 76. Pfizer Business Overview
 Table 77. Pfizer Generic and Biosimilar Pharmaceuticals Product
 Table 78. Pfizer Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 79. Pfizer Recent Development
 Table 80. Novo Nordisk Company Details
 Table 81. Novo Nordisk Business Overview
 Table 82. Novo Nordisk Generic and Biosimilar Pharmaceuticals Product
 Table 83. Novo Nordisk Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 84. Novo Nordisk Recent Development
 Table 85. Eli Lilly Company Details
 Table 86. Eli Lilly Business Overview
 Table 87. Eli Lilly Generic and Biosimilar Pharmaceuticals Product
 Table 88. Eli Lilly Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 89. Eli Lilly Recent Development
 Table 90. Novartis Company Details
 Table 91. Novartis Business Overview
 Table 92. Novartis Generic and Biosimilar Pharmaceuticals Product
 Table 93. Novartis Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 94. Novartis Recent Development
 Table 95. Merck Company Details
 Table 96. Merck Business Overview
 Table 97. Merck Generic and Biosimilar Pharmaceuticals Product
 Table 98. Merck Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 99. Merck Recent Development
 Table 100. 3sbio Company Details
 Table 101. 3sbio Business Overview
 Table 102. 3sbio Generic and Biosimilar Pharmaceuticals Product
 Table 103. 3sbio Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 104. 3sbio Recent Development
 Table 105. Changchun High Tech Company Details
 Table 106. Changchun High Tech Business Overview
 Table 107. Changchun High Tech Generic and Biosimilar Pharmaceuticals Product
 Table 108. Changchun High Tech Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 109. Changchun High Tech Recent Development
 Table 110. CP Guojian Company Details
 Table 111. CP Guojian Business Overview
 Table 112. CP Guojian Generic and Biosimilar Pharmaceuticals Product
 Table 113. CP Guojian Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 114. CP Guojian Recent Development
 Table 115. Biotech Company Details
 Table 116. Biotech Business Overview
 Table 117. Biotech Generic and Biosimilar Pharmaceuticals Product
 Table 118. Biotech Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 119. Biotech Recent Development
 Table 120. Gelgen Company Details
 Table 121. Gelgen Business Overview
 Table 122. Gelgen Generic and Biosimilar Pharmaceuticals Product
 Table 123. Gelgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 124. Gelgen Recent Development
 Table 125. Innovent Company Details
 Table 126. Innovent Business Overview
 Table 127. Innovent Generic and Biosimilar Pharmaceuticals Product
 Table 128. Innovent Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 129. Innovent Recent Development
 Table 130. Dong Bao Company Details
 Table 131. Dong Bao Business Overview
 Table 132. Dong Bao Generic and Biosimilar Pharmaceuticals Product
 Table 133. Dong Bao Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 134. Dong Bao Recent Development
 Table 135. Ganlee Company Details
 Table 136. Ganlee Business Overview
 Table 137. Ganlee Generic and Biosimilar Pharmaceuticals Product
 Table 138. Ganlee Revenue in Generic and Biosimilar Pharmaceuticals Business (2020-2025) & (US$ Million)
 Table 139. Ganlee Recent Development
 Table 140. Research Programs/Design for This Report
 Table 141. Key Data Information from Secondary Sources
 Table 142. Key Data Information from Primary Sources
 Table 143. Authors List of This Report


List of Figures
 Figure 1. Generic and Biosimilar Pharmaceuticals Picture
 Figure 2. Global Generic and Biosimilar Pharmaceuticals Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Generic and Biosimilar Pharmaceuticals Market Share by Type: 2024 VS 2031
 Figure 4. Monoclonal Antibodies Features
 Figure 5. Interferon Features
 Figure 6. Erythropoietin Features
 Figure 7. Insulin Features
 Figure 8. Vaccines Features
 Figure 9. Other Features
 Figure 10. Global Generic and Biosimilar Pharmaceuticals Market Size by Application (2020-2031) & (US$ Million)
 Figure 11. Global Generic and Biosimilar Pharmaceuticals Market Share by Application: 2024 VS 2031
 Figure 12. Tumor Case Studies
 Figure 13. Diabetes Case Studies
 Figure 14. Cardiovascular Case Studies
 Figure 15. Hemophilia Case Studies
 Figure 16. Other Case Studies
 Figure 17. Generic and Biosimilar Pharmaceuticals Report Years Considered
 Figure 18. Global Generic and Biosimilar Pharmaceuticals Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 19. Global Generic and Biosimilar Pharmaceuticals Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 20. Global Generic and Biosimilar Pharmaceuticals Market Share by Region: 2024 VS 2031
 Figure 21. Global Generic and Biosimilar Pharmaceuticals Market Share by Players in 2024
 Figure 22. Global Top Generic and Biosimilar Pharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic and Biosimilar Pharmaceuticals as of 2024)
 Figure 23. The Top 10 and 5 Players Market Share by Generic and Biosimilar Pharmaceuticals Revenue in 2024
 Figure 24. North America Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. North America Generic and Biosimilar Pharmaceuticals Market Share by Country (2020-2031)
 Figure 26. United States Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Canada Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Europe Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Europe Generic and Biosimilar Pharmaceuticals Market Share by Country (2020-2031)
 Figure 30. Germany Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. France Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. U.K. Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Italy Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Russia Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Nordic Countries Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Share by Region (2020-2031)
 Figure 38. China Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Japan Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. South Korea Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. India Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Australia Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Latin America Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Latin America Generic and Biosimilar Pharmaceuticals Market Share by Country (2020-2031)
 Figure 46. Mexico Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Brazil Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Share by Country (2020-2031)
 Figure 50. Turkey Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 52. UAE Generic and Biosimilar Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. Roche Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 54. Amgen Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 55. AbbVie Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 56. Sanofi-Aventis Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 57. Johnson & Johnson Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 58. Pfizer Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 59. Novo Nordisk Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 60. Eli Lilly Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 61. Novartis Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 62. Merck Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 63. 3sbio Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 64. Changchun High Tech Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 65. CP Guojian Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 66. Biotech Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 67. Gelgen Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 68. Innovent Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 69. Dong Bao Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 70. Ganlee Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2020-2025)
 Figure 71. Bottom-up and Top-down Approaches for This Report
 Figure 72. Data Triangulation
 Figure 73. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Leap India

SIMILAR REPORTS

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart